S. M. Campos

A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer

Michael V. Seiden, Franco M. Muggia, Allan Astrow et al. · Gynecologic Oncology · 2004 · 84 citations

Tumoral Pathology, Medicine, Pathology +6

A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer

Akila N. Viswanathan, Hang Lee, Ross S. Berkowitz et al. · Gynecologic Oncology · 2013 · 27 citations

Concurrent Bevacizumab, Radiation Therapy, Medicine +8

Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors

S. M. Campos, Ursula A. Matulonis, Richard T. Penson et al. · Gynecologic Oncology · 2003 · 24 citations

Surgical Oncology, Oncology, Tumoral Pathology +8

Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors

R. T. Penson, S A Cannistra, Michael V. Seiden et al. · Journal of Clinical Oncology · 2006 · 22 citations

First Line Chemotherapy, Consolidation Bevacizumab, Medicine +14

A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy

S. M. Campos, Michael V. Seiden, Amar Oza et al. · Journal of Clinical Oncology · 2004 · 15 citations

Gynecology, Pathology, Pharmacotherapy +18